Efficacy, Safety, and Tolerability Considerations in the Novel Treatment of Major Depressive Disorder (66 Minutes)

Jointly sponsored by Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for this activity has been provided by an educational grant from Bristol-Myers Squibb.

Release Date: June 5, 2009
Termination Date: June 5, 2011

• Major Depressive Disorder: Barriers to Treatment
By Andrew Nierenberg, MD (start time: 9:52)

• Perceptions of Efficacy, Safety, and Tolerability: Impact on Evaluating New Treatments
By Sidney Kennedy, MD, FRCPC (start time: 18:50)

• Novel Treatments For Major Depressive Disorder
By R. Bruce Lydiard, PhD, MD (start time: 31:50)

• Future Drugs for the Treatment of Depression: The Need to Look Beyond Monoamine Systems
By Mark Hyman Rapaport, MD (start time: 48:10)

[Click here for PsychCast™]

New Perspectives in the Diagnosis and Management of Insomnia (59 Minutes)

Jointly sponsored by Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for this activity has been provided by an educational grant from sanofi-aventis.

Release Date: January 2009
Termination Date: January 31, 2011

• Introduction
By Milton K. Erman, MD (start time: 7:12)

• Insomnia Etiology and Comorbidity
By Milton K. Erman, MD (start time: 14:10)

• Gender, Age, and the Risk of Insomnia
By Phyllis Zee, MD, PhD (start time: 26:25)

• New Directions in the Pharmacologic Treatment of Insomnia
By David Neubauer, MD (start time: 39:48)

[Click here for PsychCast™]

Selections from the Alzheimer's Disease Summit: Translating Research Advances Into Clinical Practice

Jointly sponsored by Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for this activity has been provided by educational grants from Forest Pharmaceuticals Inc., Eisai Inc., Medivation, Inc., and Elan Pharmaceuticals, Inc.

Release Date: December 2008
Termination Date: December 31, 2010

Advances in Clinical Assessment (61 Minutes)
[Click title for PsychCast™]

• What are the Short Clinical Assessments Applicable to Busy Practices?
By Ziad Nasreddine, MD (start time: 7:45)

• Neuropsychological Characterization of Dementia Patients: When Is it Helpful?
By Kathleen Welsh-Bohmer, PhD (start time: 24:40)

• Computerized Neuropsychological Assessments: Ready for Prime Time?
By Ellen Woo, PhD (start time: 43:33)

Advances in Neuroimaging and Biomarkers (71 Minutes)
[Click title for PsychCast™]

• Use of Magnetic Resonance Imaging to Identify Mild Cognitive Impairment: Who Should Be Imaged?
By Liana Apostolova, MD (start time: 7:40)

• FDG and Amyloid Positron Emission Topography: What Information Do These Provide?
By Mark A. Mintun, MD (start time: 26:10)

• Cerebrospinal Fluid: When Is it Worthwhile to Do a Lumbar Puncture?
By Elaine Peskind, MD (start time: 49:43)

Click here to read the extended CME Expert Review Supplement related to this activity

Best Practices in Adult ADHD: Special Considerations (63 Minutes)

Jointly sponsored by
Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for this activity has been provided by an educational grant from Shire Pharmaceuticals Inc.

Release Date: November 2008
Termination Date: November 30, 2010

[Click here for PsychCast™]

Best Practices in Adult ADHD: Neurobiology, Pharmacology, and Emerging Treatments (85 Minutes)

Jointly sponsored by
Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for this activity has been provided by an educational grant from Shire Pharmaceuticals Inc.

Release Date: October 2008
Termination Date: October 31, 2010

[Click here for PsychCast™]

Best Practices in Adult ADHD: Epidemiology, Impairments, and Differential Diagnosis (70 Minutes)

Jointly sponsored by
Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for this activity has been provided by an educational grant from Shire Pharmaceuticals Inc.

Release Date: September 2008
Termination Date: September 30, 2010

[Click here for PsychCast™]

Adult Attention-Deficit/Hyperactivity Disorder and the Role of Depression (72 Minutes)

Jointly sponsored by
Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for this activity has been provided by an educational grant from Shire Pharmaceuticals Inc.

Release Date: June 2008
Termination Date: June 30, 2010

[Click here for PsychCast™]

Advances in the Diagnosis, Pathogenesis, and Management of Fibromyalgia Syndrome

A Five-Part CME PsychCast™ Series

Jointly sponsored by
Mount Sinai School of Medicine and MBL Communications, Inc.

Acknowledgement of Commercial Support: Funding for these activities have been provided through educational grants from Eli Lilly and Company and Pfizer Inc.

Release Date: May 2008
Termination Date: May 31, 2010

Fibromyalgia Syndrome: Presentation, Diagnosis, Differential Diagnosis, and Vulnerability (57:45 Minutes)
Faculty: I. Jon Russell, MD, PhD, and Karen G. Raphael, PhD

Psychophysical and Neurochemical Abnormalities of Pain Processing in Fibromyalgia (31:04 Minutes)
Faculty: Roland Staud, MD, and Michael Spaeth, MD

Social Influences on the Concept of Fibromyalgia (33 Minutes)
Faculty: Harold Merskey, DM, FRCP, FRCPC, FRCPsych

The Significance, Assessment, and Management of Nonrestorative Sleep in Fibromyalgia Syndrome (31:33 Minutes)
Faculty: Harvey Moldofsky, MD, Diploma in Psychiatry, FRCPC, FAPA

Fibromyalgia Syndrome: Approach to Management (52:36 Minutes)
Faculty: I. Jon Russell, MD, PhD

Update on the Etiology and Treatment of Schizophrenia and Bipolar Disorder (41:03 Minutes)

[Click here for Psychcast™]

Neuroprotection: A New Strategy in the Treatment of Schizophrenia (63:51 Minutes)

[Click here for Psychcast™]